

¹⁸⁸Rhenium-TDD-Lipiodol in Treatment of Inoperable Primary Hepatocellular Carcinoma—A Case Report

F X Sundram,**FAMS, MSc, DMRT*, S W K Yu,***PhD, MRPS*, J M Jeong,****PhD*, S Somanesan,*****BSc*,
J Premaraj,⁺*FAMS, MBBS, FRCS*, M M Saw,⁺⁺*MBBS*, B S Tan,⁺⁺⁺*FAMS, MBBS, FRCR*

Abstract

Introduction: The aim of this study was to investigate the potential of using ¹⁸⁸Re Lipiodol for selective internal radiation therapy of inoperable hepatocellular carcinoma (HCC). **Clinical Picture:** A 33-year-old female with poorly-differentiated multicentric HCC, elevated alpha-fetoprotein (AFP) and increased serum alkaline phosphatase. **Treatment:** Over a 2-month interval, the patient was treated twice with 4GBq of ¹⁸⁸Re-TDD-Lipiodol. **Outcomes:** There was good localisation of ¹⁸⁸Re Lipiodol in the tumours, but also in thyroid (first treatment) and gastrointestinal tract (both treatments). So far (5 months post-treatment), the patient remains well with stable disease. **Conclusions:** ¹⁸⁸Re Lipiodol can be an effective radiopharmaceutical for the treatment of HCC; however, more work must be done to minimise the uptake in bowel.

Ann Acad Med Singapore 2001; 30:542-5

Key words: Selective internal radiation therapy, Radiopharmaceutical, Radiation absorbed dose

* Head and Senior Consultant

** Radiopharmacist

*** Radiation Physicist

++ Medical Laboratory Technician

Department of Nuclear Medicine, Singapore General Hospital

+++ Consultant

Department of Diagnostic Radiology, Singapore General Hospital

*** Associate Professor

Department of Nuclear Medicine, Seoul National University Hospital, Korea

+ Hepatobiliary Surgeon

Private Practice

Address for Reprints: Dr Felix X Sundram, Department of Nuclear Medicine, Singapore General Hospital, 1 Hospital Drive, Singapore 169608.

E-mail: gnmfxs@sgh.com.sg